Hyperion Therapeutics (HPTX) Files $57.5M IPO
Tweet Send to a Friend
Up)
Hyperion Therapeutics (Nasdaq: HPTX) filed a registration with the U.S. Securities and Exchange Commission for an Initial Public Offering of its Common Stock. The proposed maximum offering price is $57.5 million. Hyperion plans to list on the Nasdaq Global Market under the ticker "HPTX."
The offering is being made through Leerink Swann, Cowen and Company, and Needham & Company.
Hyperion is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat disorders in the areas of orphan diseases and hepatology.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The offering is being made through Leerink Swann, Cowen and Company, and Needham & Company.
Hyperion is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat disorders in the areas of orphan diseases and hepatology.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Hyperion Therapeutics Added to NASDAQ Biotechnology Index (NBI)
- Semi-Annual Changes to the NASDAQ Biotechnology Index
- Dan Loeb Builds Massive Stake in Sony (SNE), Wants Entertainment Arm Split
Create E-mail Alert Related Categories
IPOsRelated Entities
Needham & Company, Cowen & Co
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
